Table III.
Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.
| Pt. ID | Time point | Proportion of nucleated cells (%) | |||
|---|---|---|---|---|---|
| CD34+/CD19+ | CD34+/CD19− | CD34−/CD19+ | CD34−/CD19− | ||
| BCP‐ALL | |||||
| 4 | Diagnosis | 85 | 0·7 | 7 | 7 |
| Navitoclax | 72 ± 11 | 6 ± 3* | 21 ± 12 | 2 ± 1 | |
| Venetoclax | 76 ± 1 | 10 ± 6* | 13 ± 7 | 1 ± 0·2 | |
| 9 | Diagnosis | 1·8 | 0·2 | 93·9 | 4·1 |
| Navitoclax | 1 ± 1 | 0·1 ± 0·1 | 92 ± 1 | 8 ± 0·5* | |
| Venetoclax | 1 ± 1 | 0·2 ± 0·1 | 86 ± 1 | 13 ± 1* | |
| Std Chem | 0·5 ± 0·4* | 0·5 ± 0·2 | 52 ± 41 | 47 ± 41 | |
| 14 | Diagnosis | 25 | 0·5 | 72·6 | 1·9 |
| Navitoclax | 9 ± 2 | 2 ± 2 | 78 ± 11 | 12 ± 9* | |
| Venetoclax | 11 ± 5 | 1 ± 0·4 | 77 ± 4 | 10 ± 4* | |
| Std Chem | 0·9 ± 0·1*** | 0·1 ± 0·01 | 87 ± 0·7 | 12 ± 0·9** | |
| CD34+/CD7+ | CD34+/CD7 − | CD34 − /CD7+ | CD34 − /CD7 − | ||
| T‐ALL | |||||
| 22 | Diagnosis | 0·1 | 0 | 99 | 0·05 |
| Navitoclax | 0 | 0 | 93 ± 1 | 7 ± 1** | |
| Venetoclax | 0 | 0 | 85 ± 5 | 15 ± 5** | |
| Std Chem | 0·9 ± 0·03 | 0·1 ± 0·1 | 77 ± 14 | 22 ± 14 | |
| 25 | Diagnosis | 20·1 | 0·3 | 75·2 | 4·4 |
| Navitoclax | 0·2 ± 0·2** | 0·4 ± 0·4 | 31 ± 2* | 68 ± 1** | |
| Venetoclax | 0 | 0 | 33* | 67** | |
| Std Chem | 0·6 ± 0·1*** | 0·4 ± 0·1 | 68 ± 9 | 31 ± 9** | |
| 31 | Diagnosis | 2 | 14 | 34 | 50 |
| Navitoclax | 9 ± 5 | 2 ± 2 | 67 ± 27 | 22 ± 17 | |
| Venetoclax | 28 ± 13 | 2 ± 1 | 65 ± 22 | 5 ± 3 | |
Data shows the immunophenotype of primary patient samples at diagnosis and the immunophenotype of cells recovered from the bone marrow of NSG mice engrafted with these patient samples then treated with navitoclax, venetoclax or standard chemotherapeutics (Std Chem: dexamethasone, vincristine, L‐asparaginase ± daunorubicin). Bold text indicates significant difference from inoculated primary sample (*, P < 0·05; **, P ≤ 0·01; ***, P ≤ 0·001).
ALL, acute lymphoblastic leukaemia; BCP, B‐cell precursor; T‐ALL, T‐cell ALL.